Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

Launched by TONGJI HOSPITAL · Sep 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called 18F-FES PET/CT, which helps doctors see how estrogen receptors (ER) are expressed in breast cancer. This is important because understanding the levels of estrogen receptors can help in deciding the best treatment options for patients with breast cancer, especially for those with specific types like triple-negative breast cancer or estrogen-receptor-negative breast cancer. The goal is to see how well this imaging technique works in evaluating these receptors in both primary (original) and metastatic (spread) breast cancer cases.

To participate in this trial, you need to be over 18 years old and have a confirmed diagnosis of breast cancer. You will also need to sign a consent form agreeing to take part in the study. Unfortunately, pregnant women and those with serious health issues that might interfere with the imaging cannot join. If you do participate, you can expect to undergo the PET/CT scan, which is a safe and non-invasive way to gather important information about your cancer. The study is currently looking for participants, and this may provide valuable insights into breast cancer treatment and care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • More than 18 years old
• • Patients with pathologically confirmed breast cancer
• • Sign the informed consent form
• Exclusion Criteria:
• • Pregnant women
• • Severe underlying diseases that cannot cooperate with PET examination